Skip to contentS
Starling Oncology, Inc.
S
STLNStarling Oncology, Inc. Q3 2024 · 10-Q
Revenue$99.90M$99.90M+21.8% vs Q3 2023 Net Income-$16.11M-$16.11MN/M vs Q3 2023 EPS Diluted-$0.18-$0.18N/M vs Q3 2023 Operating Income-$13,853,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Starling Oncology, Inc. · CIK 1799191 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$1,221,000N/M Margins · derivedOperating margin-13.9%+3.1 pt vs Q3 2023
Net margin-16.1%+5.1 pt vs Q3 2023
ended Sep 30, 2024 · filed Nov 13, 2024 · 44 d after period end